Herz-Kreislauf-Erkrankungen und Mikronährstoffe

Zusammenfassung

Herz-Kreislauf-Erkrankungen stellen die häufigste Todesursache in Deutschland dar. ­Immer mehr Medikamente v. a. für ältere Menschen werden die anstehenden medi­zinischen Probleme der älter werdenden Gesellschaft nicht lösen. Praktikable Lösungsansätze kristallisieren sich im Bereich der Lebensstilmedizin heraus: Frühzeitige Lebensstiländerungen mit Reduktion der Risikofaktoren, gesunder Ernährung und Bewegung zeigen in Studien gute Ergebnisse. Große Bedeutung kommt dabei auch kardioprotektiven Mikronährstoffen zu, sowohl in der Prävention als auch Therapie.

Abstract

Cardiovascular diseases are the most common cause of death in Germany. The increasing amount of drugs, especially for older people, will not solve the upcoming medical problems of the aging society. Lifestyle medicine offers practicable approaches to solve this problem: an early change of lifestyle including a reduction of risk factors, healthy nutrition, and physical activity shows good results in studies. Micronutrients are of great importance in prevention as well as in therapy.

Schlüsselwörter

Herz-Kreislauf-Erkrankungen - Mikronährstoffe - Ernährung - Cholesterin - Arteriosklerose - Statine

Keywords

Cardiovascular diseases - micronutrients - nutrition - cholesterol - arteriosclerosis - statins

• Literatur

• 1 Yerushalmy J, Hilleboe H. Fat in the diet and mortality from heart disease; a methodologic note. N Y State J Med 1957; 14: 2343-2354
• 2 Anderson et al. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-2180
• 3 MRFIT Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982; 248: 1465-1477
• 4 Werkö L. Analysis of the MRFIT screenees: a methodological study. J Intern Med 1995; 237: 507-518
• 5 WHO report 2011, OECD Statistics.
• 6 Carroll MD, Lacher DA, Sorlie PD et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773-1781
• 7 Kurt Lande / Warren Sperry in Archives of Pathology, 1936
• 8 Mathur KS, Patney NL, Kumar V et al. Serum cholesterol and atherosclerosis in man. Circulation 1961; 23: 847-852
• 9 Paterson JC. Serum lipid levels and the severity of coronary and cerebral atherosclerosis in adequately nourished men, 60 to 69 years of age. Circulation 1963; 27: 229-236
• 10 Hoevenaar-Blom MP, Wendel-Vos GC, Spijkerman AM et al. Cycling and sports, but not walking, are associated with 10-year cardiovascular disease incidence: the MORGEN Study. Eur J Cardiovasc Prev Rehabil 2011; 18: 41-47
• 11 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364
• 12 Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
• 13 Ray KK, Seshasai SR, Ergou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010; 170: 1024-1031
• 14 Jenkins DJ, Kendall CW, Marchie A et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290: 502-551
• 15 Rosenfeldt FL, Haas SJ, Krum H. Coenzyme Q 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007; 21: 297-306
• 16 Azuma J. Adv Exp Med Biol. 1992: 315
• 17 Beyranvand MR, Khalafi MK, Roshan VD et al. Effect of taurine supplementation on exercise capacity of patients with heart ­failure. J Cardiol 2011; 57: 333-337
• 18 Buijsse B, Feskens EJ, Kok FJ et al. Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 2006; 166: 411-417